2024

Educational materials on the risks of infusion reactions, medication errors associated with home infusions, and risks for pregnant women and women of reproductive potential during treatment with the medicinal product XENPOZYME (olipudase alfa)

Educational materials for healthcare professionals on the risks of infusion reactions, errors during home infusions, and risks for pregnant women and women of reproductive potential during treatment. generated automatically

Communication materials on the risk of neurodevelopmental disorders in children born to men who used valproates (DEPAKINE®, DEPAKINE® ENTERIC 300, DEPAKINE CHRONO® 300 mg, DEPAKINE CHRONO® 500 mg)

Information materials for healthcare professionals and patients on the risk of neurodevelopmental disorders in children whose parents used valproates. They contain recommendations on preventing such risks. generated automatically

Informational letter to healthcare professionals regarding the risk of anaphylactic reactions several months or years after the start of treatment with glatiramer acetate (COPAXONE®-TEVA, COPAXONE 40).

An information letter for healthcare professionals on the risk of anaphylactic reactions that may occur several months or years after the start of treatment with glatiramer acetate. Intended to inform healthcare professionals. compiled automatically

Informational letter to healthcare professionals regarding the increased risk of immunogenicity in response to the use of the medicinal product PROPES

Information letter to healthcare professionals regarding the medicinal product VINITEL® (valproate), syrup, 200 mg/5 ml “New measures regarding the potential risk of neurodevelopmental disorders in children born to men who took valproates (valproate) during the 3 months before conception.”

Information letter for healthcare professionals on new measures regarding the potential risk of neurodevelopmental disorders in children born to men who took valproates during the three months before conception. generated automatically

Information letter addressed to healthcare specialists “DIMETHYL FUMARATE, modified-release capsules 120 mg, important information on minimizing the risk of progressive multifocal leukoencephalopathy (PML) in patients with mild lymphopenia when using dimethyl fumarate”

Information letter for healthcare professionals on minimizing the risk of progressive multifocal leukoencephalopathy in patients with mild lymphopenia when using dimethyl fumarate. It contains safety recommendations and guidance on monitoring patients during treatment. generated automatically

Communication materials on the safe use of the medicinal product LENANGIO (lenalidomide)

Information letter to healthcare professionals on the medicinal product Plaquenil® (hydroxychloroquine): potential risk of serious congenital malformations and new risks

Communication materials for healthcare professionals and patients on the potential risk of HIV seroconversion and development of resistance with the use of the medicinal product Apretude

Guide for healthcare professionals on the use of the medicinal product OBADZHIO® (teriflunomide) and the Patient Card with safety information to be aware of when using the medicinal product OBADZHIO®

Guide and patient card with safety information on the use of teriflunomide: intended for healthcare professionals and patients, they contain recommendations on the use of the medicinal product and important warnings. compiled automatically